High expression of MAGOH/MAGOHB was correlated with worse overall survival in 932 glioma patients from three independent cohorts (Shanghai ChangZheng Hospital, 60 patients; TCGA, from 674 glioma samples, 665 are from patients presenting outcome (survival) information; CGGA, 207 patients) even after a co-factor stratification (Figure 2C and Supplementary Figure S2). Here, MAGOHB is linked to central nervous system cancer.